welcome
Investor's Business Daily

Investor's Business Daily

Health

Health

Evolus stock retook its 50-day and 200-day moving averages on strong fourth-quarter report and 2025 guidance

Investor's Business Daily
Summary
Nutrition label

70% Informative

Evolus preannounced $79 million in fourth-quarter sales, up 30% from the year-earlier period .

In November , the company lowered its guidance for the year by 1% , leading to a single-day 15% stock dive.

The company also now expects the Food and Drug Administration to approve its injectable hyaluronic acid gels in the second quarter .

VR Score

67

Informative language

69

Neutral language

35

Article tone

formal

Language

English

Language complexity

45

Offensive language

not offensive

Hate speech

not hateful

Attention-grabbing headline

detected

Known propaganda techniques

not detected

Time-value

short-lived

Affiliate links

no affiliate links